Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-62.29M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.60 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -28.61% |
| Return on Assets (Trailing 12 Months) | -18.05% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.91 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.91 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.08 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.10 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.53 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.01 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 74.51M |
| Free Float | 53.28M |
| Market Capitalization | $403.12M |
| Average Volume (Last 20 Days) | 0.52M |
| Beta (Past 60 Months) | 0.42 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 28.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 46.64% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |